NovartisNVS
NVS
About: Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Employees: 75,883
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
42% more first-time investments, than exits
New positions opened: 149 | Existing positions closed: 105
1% more funds holding
Funds holding: 1,295 [Q3] → 1,313 (+18) [Q4]
0.1% less ownership
Funds ownership: 6.04% [Q3] → 5.95% (-0.1%) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 413 | Existing positions reduced: 464
15% less capital invested
Capital invested by funds: $15.2B [Q3] → $12.9B (-$2.3B) [Q4]
24% less call options, than puts
Call options by funds: $190M | Put options by funds: $250M
31% less funds holding in top 10
Funds holding in top 10: 13 [Q3] → 9 (-4) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for NVS.
Financial journalist opinion
Based on 23 articles about NVS published over the past 30 days
Positive
Reuters
9 hours ago
NFL signs Novartis as first pharmaceutical partner-source
The National Football League has signed its first-ever pharmaceutical partner in a multi-year deal with Switzerland-based firm Novartis , a league source told Reuters on Thursday.
Neutral
GlobeNewsWire
9 hours ago
Novartis Pharmaceuticals and Folia Health Partner on Innovative App-Based Study to Assess Real-World Experience of IgA Nephropathy
BOSTON, March 13, 2025 (GLOBE NEWSWIRE) -- Today, Folia Health and Novartis Pharmaceuticals, Inc. proudly announce their collaboration on an innovative, at-home observational real-world evidence initiative supporting individuals with IgA nephropathy. This ground-breaking study will leverage Folia's cutting-edge technology platform, allowing participants to track changes and quality of life impacts based on the symptoms most relevant to them- whether commonly associated with IgAN or not- alongside their individual treatment plan during an initial six-month observational period. By enabling participants to self-select and define what's most relevant to them, rather than relying solely on pre-specified patient-reported outcomes (PROs), this approach provides a comprehensive and nuanced understanding of the lived experiences of IgAN.
Positive
Zacks Investment Research
1 day ago
Why Novartis (NVS) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Neutral
Zacks Investment Research
6 days ago
3 Top Cancer Biotechs to Keep An Eye On in 2025
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Neutral
GlobeNewsWire
6 days ago
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2025 Annual General Meeting
Basel, March 7, 2025 – Novartis shareholders today agreed to the Board of Directors' recommendations for all proposed resolutions at the company's Annual General Meeting (AGM). A total of 1,693 shareholders were present at the meeting held in Basel, representing approximately 57.42% of the issued shares of Novartis.
Positive
Seeking Alpha
1 week ago
10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil
The trade war is causing market volatility, with stocks falling and bonds performing well as investors seek hedges against economic slowdown fears. Dividend aristocrats, particularly low-volatility, defensive ones, offer a stable investment strategy during trade war turmoil. They provide dependable income and lower downside risk. The recommended 10 low volatility dividend aristocrats include Johnson & Johnson, PepsiCo, and Kimberly-Clark, offering a 4% yield and strong long-term return potential.
Neutral
Reuters
1 week ago
Novartis not panicking over potential US pharmaceutical tariffs, chairman says
Novartis is not panicking about higher tariffs on pharmaceutical imports that U.S. President Donald Trump could impose, the drug maker's Chairman Joerg Reinhardt said in an interview published on Thursday.
Positive
Zacks Investment Research
1 week ago
Novartis Gets CHMP Opinion for Label Expansion of Fabhalta
The CHMP recommends granting a marketing authorization to NVS' Fabhalta for the treatment of adults with C3 glomerulopathy, an ultra-rare, progressive kidney disease with no currently approved treatment.
Positive
The Motley Fool
1 week ago
3 Dividend Stocks That Are No-Brainer Buys Right Now
It can be difficult to decide which dividend stocks to buy. After all, more than 5,700 of them trade on U.S. stock exchanges.
Neutral
GlobeNewsWire
1 week ago
Novartis data presentations at AAAAI and AAD underscore commitment to advancing treatment of hidradenitis suppurativa (HS) and chronic spontaneous urticaria (CSU)
Basel, February 28, 2025 – Novartis announced today it will present data from 17 abstracts, including investigator-initiated trials, across its immunology portfolio at the 2025 American Academy of Allergy Asthma and Immunology (AAAAI) and World Allergy Organization (WAO) Joint Congress and the 2025 American Academy of Dermatology (AAD) Annual Meeting.
Charts implemented using Lightweight Charts™